User:Mr. Ibrahem/Cangrelor

Mr. Ibrahem/Cangrelor
Clinical data
Trade names	Kengreal, Kengrexal, Canreal
Other names	AR-C69931MX
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Kengreal; US FDA: Kengreal;
Routes of; administration	Intravenous
Drug class	P2Y12 inhibitor
Legal status
Legal status	US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	100% (IV)
Protein binding	~97–98%.
Metabolism	Rapid deactivation in the circulation (independent of CYP system)
Elimination half-life	~3–6 minutes
Excretion	Kidney (58%), Bile duct (35%)
Identifiers
	IUPAC name [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid;
Chemical and physical data
Formula	C17H25Cl2F3N5O12P3S2
Molar mass	776.35 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CSCCNC1=NC(=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)SCCC(F)(F)F;
	InChI InChI=1S/C17H25Cl2F3N5O12P3S2/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32)/t8-,10-,11-,14-/m1/s1 ; Key:PAEBIVWUMLRPSK-IDTAVKCVSA-N ;
	(what is this?)

Cangrelor, sold under the brand name Kengreal among others, is a medication used in those undergoing percutaneous coronary intervention (PCI) to prevent blood clots.^[2] It is used with aspirin.^[2] It is given by injection into a vein.^[1]

Common side effects include bleeding and shortness of breath.^[2] Other side effects may include allergic reactions.^[2] Safety in pregnancy is unclear.^[1] It is a P2Y₁₂ inhibitor which blocks platelets from sticking together.^[1]^[2]

Cangrelor was approved for medical use in the United States and Europe in 2015.^[1]^[2] In the United Kingdom 50 mg costs the NHS about £250 as of 2021.^[3] This amount in the United States costs about 830 USD.^[4]

References[edit]

^ ^a ^b ^c ^d ^e "Cangrelor Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 29 December 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h "Kengrexal". Archived from the original on 17 April 2021. Retrieved 29 December 2021.
^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 225. ISBN 978-0857114105.
^ "Kengreal Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 April 2021. Retrieved 29 December 2021.

[AHFS2021-1] "Cangrelor Monograph for Professionals". Drugs.com. Archived from the original on 21 January 2021. Retrieved 29 December 2021.

[EPAR2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h "Kengrexal". Archived from the original on 17 April 2021. Retrieved 29 December 2021.

[BNF81-3] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 225. ISBN 978-0857114105.

[4] "Kengreal Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 17 April 2021. Retrieved 29 December 2021.

[1]

[2]

[3]

[4]